Angiogenic Effects Despite Limited Cell Survival of Bone Marrow-Derived Mesenchymal Stem Cells under Ischemia

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) are multipotent and secrete angiogenic factors, which could help patients with occlusive arterial diseases. We hypothesize that MSCs, in comparison to fibroblasts, survive better under hypoxic conditions in vitro and in vivo. MSCs and fibroblasts from L2G mice expressing firefly luciferase and GFP were cultured in normoxic and hypoxic conditions for 24 hours. In vitro cell viability was tested by detecting apoptosis and necrosis. MSCs released higher amounts of VEGF (281.1 ± 62.6 pg/ml) under hypoxic conditions compared to normoxia (154.9 ± 52.3 pg/ml, p = NS), but were less tolerant to hypoxia (45 ± 7.9 %) than fibroblasts (28.1 ± 3.6 %, p = NS). A hindlimb ischemia model was created by ligating the femoral artery of 18 FVB mice. After one week, 1 × 106 cells (MSCs, fibroblasts or saline) were injected into the limb muscles of each animal (n = 6 per group). Bioluminescence measurement to assess the viability of luciferase positive cells showed significant proliferation of MSCs on day four compared to fibroblasts (p = 0.001). Three weeks after cell delivery, the capillary to muscle fiber ratio of ischemic areas was analyzed. In the MSC group, vessel density was significantly higher than in the fibroblast or control group (0.5 ± 0.08 and 0.3 ± 0.03). Under hypoxia, MSCs produced more VEGF compared to normal conditions and MSC transplantation into murine ischemic limbs led to an increase in vessel density, although MSC survival was limited. This study suggests that MSC transplantation may be an effective and clinically relevant tool in the therapy of occlusive arterial diseases.

myocardial infarction - stem cells - angiogenesis

References

• 1 Aghi M, Chiocca E A. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumours.  Mol Ther. 2005;  12 994-1005
• 2 Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner J M. Isolation of putative progenitor endothelial cells for angiogenesis.  Science. 1997;  275 964-967
• 3 Pittenger M F, Mackay A M, Beck S C, Jaiswal R K, Douglas R, Mosca J D, Moorman M A, Simonetti D W, Craig S, Marshak D R. Multilineage potential of adult human mesenchymal stem cells.  Science. 1999;  284 143-147
• 4 Moscoso I, Centeno A, Lopez E, Rodriguez-Barbosa J I, Santamarina I, Filgueira P, Sanchez M J, Dominguez-Perles R, Penuelas-Rivas G, Domenech N. Differentiation “in vitro” of primary and immortalized porcine mesenchymal stem cells into cardiomyocytes for cell transplantation.  Transplant Proc. 2005;  37 481-482
• 5 Chen S L, Fang W W, Ye F, Liu Y H, Qian J, Shan S J, Zhang J J, Chunhua R Z, Liao L M, Lin S, Sun J P. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction.  Am J Cardiol. 2004;  94 92-95
• 6 Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K, Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo.  Gene Ther. 2003;  10 621-629
• 7 Fukuda K, Fujita J. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice.  Kidney Int. 2005;  68 1940-1943
• 8 Ziegelhoeffer A, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature.  Circ Res. 2004;  94 230-238
• 9 O'Neill 4th T J, Wamhoff B R, Owens G K, Skalak T C. Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells.  Circ Res. 2005;  97 955-957
• 10 Schrepfer S, Deuse T, Lange C, Katzenberg R, Reichenspurner H, Robbins R C, Pelletier M P. Simplified protocol to isolate, purifiy, and cell culture expand mesenchymal stem cells.  Stem Cells Dev. 2007;  16 105-107
• 11 Jacobi J, Tam B Y Y, Wu G, Hoffmann J, Cooke J P, Kuo C J. Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia.  Circulation. 2004;  110 2424-2429
• 12 Kinnaird T, Stabile E, Burnett M S, Lee C W, Barr S, Fuchs S, Epstein S E. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms.  Circ Res. 2004;  94 678-685
• 13 Rutherford R B, Baker J D, Ernst C, Johnston K W, Porter J M, Ahn S, Jones D N. Recommended standards for reports dealing with lower extremity ischemia: revised version.  J Vasc Surg. 1997;  26 517-538
• 14 Badea C T, Fubara B, Hedlund L W, Johnson G A. 4-D micro-CT of the mouse heart.  Mol Imaging. 2005;  4 110-116
• 15 Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T, Kangawa K, Kitamura S. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia.  Cardiovasc Res. 2005;  66 543-551
• 16 Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki T, Duan J, Imaizumi T. Augmentation of postnatal neovascularization with autologous bone marrow transplantation.  Circulation. 2001;  103 897-903
• 17 Annabi B, Lee Y T, Turcotte S, Naud E, Desrosiers R R, Champagne M, Eliopoulos N, Galipeau J, Beliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation.  Stem Cells. 2003;  21 337-347
• 18 Mangi A A, Noiseux N, Kong D, He H, Rezvani M, Ingwall J S, Dzau V J. Mesenchymal stem cells modified with Akt prevent remodelling and restore performance of infarcted hearts.  Nat Med. 2003;  9 1195-1201
• 19 Fukuhara S, Tomita S, Yamashiro S, Morisaki T, Yutani C, Kitamura S, Nakatani T. Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal cells to go into cardiac lineage in vitro.  J Thorac Cardiovasc Surg. 2003;  125 1470-1480
• 20 Rangappa S, Entwistle J W, Wechsler A S, Kresh J Y. Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype.  J Thorac Cardiovasc Surg. 2003;  126 124-132